Search PubMed⌕ Search

Biomedical subjects

J Jordanoglou

Publications and source records attributed to J Jordanoglou.

46 records · Page 3Linked to original sources
PubMedDate not supplied

A single-blind crossover study of two different slow release theophylline preparations.

In a single-blind crossover study, two slow release theophylline preparations were evaluated in 18 patients with chronic bronchitis or asthma without cardiac, renal or liver disease. After randomization into two groups, patients were treated, in a crossover study design, with 600 mg choline theophyllinate or 300 mg anhydrous theophylline administered orally every 12 h for 7 days. A 2-day washout period separated the two periods of treatment evaluation. Blood samples in which plasma theophylline concentration was to be measured were taken at 7.30 a.m., 2.00 p.m. and 7.30 p.m. during the last 5 days of therapy with each drug. The mean fluctuation in plasma theophylline concentration was less than or equal to 40% in all 18 patients taking choline theophyllinate yet in only 15 (83%) patients administered anhydrous theophylline. Salbutamol inhaler was more frequently required for the relief of bronchospasm when taking anhydrous theophylline than when taking choline theophyllinate (total of 41 vs 25 puffs, respectively, over 7 days). Drug-related adverse reactions occurred in four patients while taking anhydrous theophylline and in one patient while taking choline theophyllinate.

Asthma↗
PubMedDate not supplied

The effect of steroids on theophylline absorption.

The effect of hydrocortisone on plasma theophylline concentrations was evaluated in 20 patients suffering from chronic bronchitis or stable bronchial asthma. Choline theophyllinate (400 mg) was orally administered every 12 h for 8 days and blood samples were taken every 2 h during the day for the measurement of theophylline concentrations. Intravenous bolus injections of 500 or 1000 mg hydrocortisone on day 5 or day 7, respectively, did not significantly alter plasma theophylline concentrations.

Adult↗
PubMedDate not supplied

Treatment of lower respiratory tract infections with amoxycillin/clavulanic acid in adults.

Patients with lower respiratory tract infections [pneumonia (n = 16), bronchiectasis (n = 5) and acute exacerbations of chronic bronchitis (n = 44)] were treated daily with amoxycillin/clavulanic acid given either 1.2 g intravenously three times daily or 625 mg orally three times daily for 7-15 days. Symptoms, signs and sputum volume and colour were monitored daily. Chest X-ray, sputum culture and Gram-stain examinations were also carried out on days 1 and 5, and immediately after the end of the treatment. There was a clinical improvement, as indicated by the incidence of cough, dyspnoea and rales, and by sputum volume and colour in 90.8% of the patients. Microbiological improvement, as indicated by the complete elimination of sputum pathogens and pus cells, was achieved in the same proportion of patients (90.8%). In one patient, an adverse side-effect, diffuse exanthema, was noted. Amoxycillin/clavulanic acid possesses a high clinical and microbiological efficacy for lower respiratory tract infections.

Administration, Oral↗
PubMedDate not supplied

Partial effective time (teffp7): a new spirometric parameter for lung function assessment.

A new spirometric parameter for lung function assessment, the effective time at the 60-70% part of the forced vital capacity of the lung (teffp7), was considered. A total of 79 subjects were studied in two groups, A and B. In group A (5 healthy non-smokers, 22 patients with obstructive lung disease and 22 with pulmonary fibrosis), forced exhalation and the Helium closed-circuit technique were performed. From these tests, a number of lung function parameters were calculated, including teffp7. In group B (30 patients with bronchial asthma), the same tests were carried out before and 15 min after the administration of two puffs of a bronchodiluent, a beta 2-stimulant. From these tests, various lung function measures were again calculated, as well as the change in these parameters after bronchodilatation. The study shows that teffp7 is a more sensitive index than all the other parameters considered for determining airways condition, either in healthy subjects or in those with airways obstruction. In patients with pulmonary fibrosis, the other parameters considered are also less sensitive than teffp7. From the study of the change after bronchodilatation in patients with bronchial asthma, change in teffp7 was greater than in any other parameter. As teffp7 was the more affected parameter, it was also the more sensitive index for diagnosis of airways obstruction. In conclusion, teffp7 is a sensitive index for the diagnosis of airways obstruction or lung restriction, and it is markedly changed after bronchodilatation.

Asthma↗
PubMedDate not supplied

Clinical and microbiological evaluation of pefloxacin in lower respiratory tract infections.

Patients with Gram-negative lower respiratory tract infections (acute exacerbation of chronic bronchitis (n = 23), pneumonia (n = 4), and bronchiectasis (n = 5) were treated with pefloxacin, 400 mg twice daily, given either intravenously or orally. Symptoms, signs and sputum volume and colour were monitored daily. Chest X-rays, sputum culture and Gram-stain examinations were carried out on days 1 and 5, and immediately after the end of the treatment. There was a clinical improvement, as indicated by the incidence of cough, dyspnoea and rales, and by sputum volume and colour in 31 patients (97%). Microbiological improvement, as indicated by the complete elimination of sputum pathogens and pus cells, was achieved in 28 of the patients (88%). In one patient, an adverse effect, renal failure, occurred. These results suggest that pefloxacin is both clinically and microbiologically effective for the treatment of Gram-negative lower respiratory tract infections.

Acinetobacter Infections↗
PubMedDate not supplied

Immunohistochemical detection of p53 protein in neoplastic, preneoplastic and normal bronchial mucosa specimens obtained during diagnostic bronchoscopy.

The expression of p53 protein was evaluated immunochemically in cancer tissue, preneoplastic lesions and normal bronchial mucosa obtained during diagnostic bronchoscopy from 53 patients with lung cancer and 12 patients with benign lung diseases. In lung cancer patients, positive p53 staining was detected in 26/53 (49%) of the tumour specimens. In preneoplastic lesions p53 positive staining was found in 8 of 24 (33.3%) squamous metaplasia, 1 of 4 hyperplasia and 1 of 3 dysplasia lesions. In the same group of patients, 12 cases were found with positive p53 cells in normal bronchial mucosa. In patients with benign diseases, positive p53 staining was found in 1 of 4 cases with squamous metaplasia and in one normal mucosa. Our results provide evidence that somatic genetic alterations may occur in early stages of lung tumorigenesis, raising the possibility that molecular analyses is useful in the early diagnosis of precancerous lesions of the bronchial mucosa, and results indicate that p53 expression can be studied in small tissue specimens obtained during bronchoscopy.

Adenocarcinoma↗
PubMedDate not supplied

Evaluation of CYFRA 21-1 in malignant and benign pleural effusions.

CYFRA 21-1 was evaluated in 115 untreated patients with malignant pleural effusions (96 with primary lung cancer and 19 with non lung cancer) and 99 patients with benign pleural effusions. The levels of pleural fluid CYFRA 21-1 were from 1 to 385 times higher than those in serum, in all the examined patients. The mean level of pleural fluid CYFRA 21-1 was significantly higher in cancer patients than in patients with benign pleural effusion (96.1 ng/ml vs 26.2 ng/ml, p < 0.001). At 92% specificity for benign pleural effusion (> 50 ng/ml) the overall sensitivity of CYFRA 21-1 in malignant pleural effusions was 69.6%. When the histology was considered the highest sensitivity was found in squamous cell lung cancer (90%), followed by adenocarcinoma cell lung cancer (74%), non lung cancer (54%) and small cell lung cancer (25%). These results indicate that CYFRA 21-1 could be a useful pleural fluid marker in discriminating benign from malignant pleural effusion and particularly from those due to squamous and adenocarcinoma cell lung cancer.

Adenocarcinoma↗